Japan· JP-4900404X2026
オナセムノゲン アベパルボベク
A medicinal product containing オナセムノゲン アベパルボベク, registered in Japan by ノバルティス ファーマ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- オナセムノゲン アベパルボベク
- Manufacturer
- ノバルティス ファーマ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
オナセムノゲン アベパルボベク in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesITVISMANovartis Innovative Technologies Inc.
- CzechiaITVISMANovartis Europharm Limited, Dublin
- BelgiumItvisma 1.2 10*14 vgNovartis Europharm
- United KingdomZolgensma 20 tera vector genomes/ml (patient weight 10.1-10.5kg) solution for infusion 7 x 8.3ml vialsNovartis Pharmaceuticals UK Ltd
- NetherlandsItvisma 1,2 × 1014 vectorgenomen oplossing voor injectieNovartis Europharm Limited
- PolandItvismaNovartis Europharm Limited
- SwedenItvisma 1,2 x 10E14 vektorgenom Injektionsvätska, lösningNovartis Europharm Limited
- FinlandItvismaNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Itvisma, Zolgensma
- Liechtenstein · Itvisma, Zolgensma
- Norway · Itvisma, Zolgensma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/361006cf-76b1-4a46-8cf9-6125b55643e4 GET /v1/drugs/361006cf-76b1-4a46-8cf9-6125b55643e4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１患者当たり",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4900404X2026",
"category": "注射薬",
"price_yen": 8510,
"generic_name": "オナセムノゲン アベパルボベク",
"product_name_jp": null,
"therapeutic_class": "4900",
"transitional_expiry": "8510"
}See everything about オナセムノゲン アベパルボベク.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.